David Portnoy Buys 3,800 Shares of CRYO-CELL International, Inc. (CCEL) Stock

CRYO-CELL International, Inc. (OTCMKTS:CCEL) CEO David Portnoy bought 3,800 shares of the business’s stock in a transaction on Thursday, January 31st. The stock was bought at an average price of $6.75 per share, for a total transaction of $25,650.00. The acquisition was disclosed in a filing with the SEC, which is available through the SEC website.

Shares of CRYO-CELL International stock opened at $7.50 on Wednesday. CRYO-CELL International, Inc. has a fifty-two week low of $6.03 and a fifty-two week high of $9.64. The company has a market capitalization of $58.04 million, a price-to-earnings ratio of 26.79 and a beta of 0.09.

COPYRIGHT VIOLATION NOTICE: This piece of content was published by Enterprise Leader and is the property of of Enterprise Leader. If you are accessing this piece of content on another domain, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The original version of this piece of content can be accessed at https://theenterpriseleader.com/2019/02/06/david-portnoy-buys-3800-shares-of-cryo-cell-international-inc-ccel-stock.html.

CRYO-CELL International Company Profile

Cryo-Cell International, Inc engages in cellular processing and cryogenic cellular storage with a focus on the collection and preservation of umbilical cord blood stem cells for family use. It provides cord tissue service that stores a section of the umbilical cord tissue, a source of mesenchymal stem cells that are used in regenerative medicine to treat a range of conditions, including heart, kidney, ALS, wound healing, and auto-immune diseases.

Recommended Story: What is a bull market?

Insider Buying and Selling by Quarter for CRYO-CELL International (OTCMKTS:CCEL)

Receive News & Ratings for CRYO-CELL International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for CRYO-CELL International and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply